Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

Fractyl Health is cutting nearly a fifth of its workforce as it streamlines resources and shifts focus toward certain ...

Modular Medical develops patented insulin delivery technologies, aiming to improve access to glycemic control. Its founder, ...

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO).